Table 2. Frequency of the NQO1... | American Society of Hematology

Table 2.

Frequency of the NQO1 Polymorphism in Primary and Therapy-Related Myeloid Leukemia

Diagnosis	No. of Patients	No. (%) of Patients With			P
Diagnosis	No. of Patients	Wild-type Alleles	Heterozygous Mutation	Homozygous Mutation	P
Primary MDS, AML de novo, or CML
Observed	48	24 (50)	22 (46)	2 (4)	.27
Expected^*		28.56	16.72	2.72
t-AML
Observed	56	27 (48)	23 (41)	6 (11)	.036
Expected		34.42	18.93	2.66
Total
Observed	104	51 (49)	45 (43)	8 (8)	.050
Expected		62.98	35.65	5.38

Diagnosis	No. of Patients	No. (%) of Patients With			P
Diagnosis	No. of Patients	Wild-type Alleles	Heterozygous Mutation	Homozygous Mutation	P
Primary MDS, AML de novo, or CML
Observed	48	24 (50)	22 (46)	2 (4)	.27
Expected^*		28.56	16.72	2.72
t-AML
Observed	56	27 (48)	23 (41)	6 (11)	.036
Expected		34.42	18.93	2.66
Total
Observed	104	51 (49)	45 (43)	8 (8)	.050
Expected		62.98	35.65	5.38

Calculated from the frequency of the polymorphism reported within different ethnic groups and the racial composition of the observed group (see Materials and Methods).

View Large

This Feature Is Available To Subscribers Only